Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Igmesine: mode of action and preclinical antidepressant activity

Nov. 18, 1998

Potent and selective 5-HT1A/5-HT1B/5-HT1D receptor antagonists discovered at Pierre Fabre

Nov. 18, 1998

Putative cognition enhancer CR-2249 also exerts anxiolytic, antidepressant effects

Nov. 17, 1998

New dopamine D4 antagonist from Warner-Lambert characterized in preclinical studies

Nov. 17, 1998

Neuroprotective effects of HU-211 in soman-treated rats

Nov. 17, 1998

GPI-6150: data provide further support for development as a treatment for stroke

Nov. 17, 1998

Multiple preclinical and phase I study results presented for AIT-082 at neuroscience meeting

Nov. 17, 1998

Series of nNOS inhibitors patented by Mitsui

Nov. 17, 1998

Potent and selective nicotinic acetylcholine receptor ligands prepared at Synthelabo

Nov. 17, 1998

Ultra-short-acting neuromuscular blockers with advantages over available agents

Nov. 17, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...